A Massive New Study of 48,000 Patients Reveals One Widely Prescribed Diabetes Drug Tied to 33% Higher Risk of Serious Heart Issues
The Diabetes Drug Behind the “33% Higher Heart Risk” Headline The drug is rosiglitazone (brand name Avandia), an older type 2 diabetes medicine in the thiazolidinedione class. The headline is based on a large analysis of more than 130 clinical trials involving over 48,000 patients. Researchers found that rosiglitazone was associated with a 33% higher …









